<?xml version="1.0" encoding="UTF-8"?>
<title-group>
 <article-title>The sympathomimetic agonist mirabegron did not lower 
  <italic>JAK2</italic>-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14
 </article-title>
</title-group>
